Document is current
Any future updates will be listed below
-
Authors
Kashihara, Naoki
Okada, Hirokazu
Suzuki, Yusuke
Iwamoto, Tamio
Yasutomi, Masashi
Matsui, Masaru
Takezawa, Ryo
Ishii, Takayuki
Tomioka, Yusuke https://orcid.org/0009-0004-4165-8121
-
Funding
Funding for this research was provided by:
AstraZeneca
Gilead Sciences
Kyowa Kirin Pharmaceutical Development
GlaxoSmithKline
Daiichi-Sankyo
Takeda Pharmaceutical Company
Astellas Pharma
Otsuka Pharmaceutical
Torii Pharmaceutical
Mitsubishi Tanabe Pharma Corporation
Boehringer Ingelheim
Ono Pharmaceutical
Eli Lilly and Company
Toray Industries
Baxter International
Chugai Pharmaceutical
Bayer Yakuhin
Boehringer Ingelheim Japan
zeria
- License Information
-
More Information
Article History
Received: 21 December 2024
Accepted: 30 January 2025
First Online: 20 February 2025
Declarations
:
: N Kashihara has received consulting fees from AstraZeneca, Gilead Sciences, Kyowa Kirin, and GlaxoSmithKline, has received honoraria for lectures from Daiichi Sankyo, Takeda Pharmaceutical, Astellas Pharma, Otsuka Pharmaceutical, and Kyowa Kirin, and has received research grants from Mitsubishi Tanabe Pharma, Toray Industries, Baxter, Chugai Pharmaceutical, Kyowa Kirin, Bayer Pharm, Ono Pharm, Daiichi Sankyo, Nippon Boehringer Ingelheim, Astellas Pharma, and Takeda Pharmaceutical. H Okada has received honoraria for lectures from Kyowa Kirin, Daiichi Sankyo, AstraZeneca, Torii Pharm., Mitsubishi Tanabe Pharm, Boehringer Ingelheim, Ono Pharm, Eli Lilly Pharm, has received research grants from Kyowa Kirin, Bayer Pharm, Chugai Pharm, and has received subsidies or donations from Chugai Pharm., Ono Pharm., Kyowa Kirin, and Bayer Pharm. Y Suzuki, T Iwamoto, M Yasutomi, and M Matsui have no conflicts of interest to declare. R Takezawa, T Ishii and Y Tomioka are employees of Zeria Pharmaceuticals.
